← All candidates
27 insider filings on record.
27 filings on record.
SPROSpero Therapeutics, Inc.
NasdaqGS · Healthcare · $68.90M
$1.12
+0.89% · Sep 18
27 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 8 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$68.90M
Float
46.4M
80% public
Short % float
Pro
Price / profit
4.4
Price / future profit
—
Price / sales
1.1
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
22 more transactions on Pro →Context
Wall St
$4.00 avg target
+257.1% vs today · 1 analyst
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 3 quarters beat
Q3 '25−$0.13 act+$0.12
Q2 '25−$0.03 act+$0.35
Q1 '25−$0.25 act+$0.19
Coverage
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIsBenzinga · 06-21Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO)InvestorsHub · 06-18Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?Simply Wall St. · 12-15GSK (LSE:GSK) Wins FDA Approval For Utebzi As Momelotinib Gains Orphan TagSimply Wall St. · 06-26
The file stays open
27 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice